Komori

Notice Regarding Receipt of Dividends from a Consolidated Subsidiary

連結子会社4社から合計744百万円の配当金を受け取ることになった。当社はこの金額を2026年5月期の個別決算で営業収益に計上するが、連結業績への影響はない。

Worth reading
32Immaterial
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
744
¥ million
Wording
Definitive
How definitive the wording is.

Dividend per share

Fiscal year ending May 2026
Total dividendsTotal amount payable to all shareholders744 百万円
Dividend per share
ItemDetails
Total dividendsNot disclosed → 744 百万円
Fiscal Period CoveredFiscal year ending May 2026
Items this document does not state (10)
Dividend per shareTotal Annual DividendsPrevious-period results (per share)Record dateEffective dateSource of dividendsBreakdown of Regular, Commemorative and Special DividendsPayout ratioDividend policyWhether Submission to the General Meeting of Shareholders Is Required

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

金融商品取引法等に基づく臨時報告書の提出要件に該当するため開示した。受取配当金は2026年5月期の個別決算で営業収益に計上するが、連結子会社からの配当であるため連結業績への影響はない。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Receipt of Dividends from a Consolidated Subsidiary | Pharmarise Holdings Corporation (2796) timely disclosure | Komori